RecruitingPsoriasis of Scalp
Immune Spatial Features of Guselkumab Cutaneous Response
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Sponsor: University of California, San Francisco
You may not qualify if…
- ✕ 1. taking systemic immunosuppressives in the last 4 weeks
- ✕ 2. pregnancy
- ✕ 3. severe immunodeficiency (either from genetic or infectious causes).
- ✕ 4. tuberculosis or other active serious infection
- ✕ 5. active systemic malignancy.
- ✕ 6. breast-feeding
- ✕ 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- ✕ 8. Males who are trying to conceive
Where it's recruiting
California
San Francisco
Source: ClinicalTrials.gov · NCT05858632 · last updated 2026-06-04